Latest news

• FDA restricts use of certain antibody treatments for COVID-19

  Following a statement, the US Food and Drug Administration (FDA) has decided to revise its emergency use authorisations (EUAs) for administering a combination of Eli Lilly’s bamlanivimab and etesevimab and ... The US National Institutes of Health (NIH)

• Lilly’s combination antibody expanded to children under 12

  The FDA has expanded the emergency use for bamlanivimab with etesevimab for the treatment of and post-exposure prophylaxis against COVID-19 in high-risk children aged under 12. ... This success was followed in February this year by the authorisation of

• EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy

  This includes Lilly’s bamlanivimab and etesevimab combination, Roche and Regeneron’s REGEN-COV (casirivimab and imdevimab), Celltrion’s regdanivimab and GlaxoSmithKline/Vir Biotech’s sotrovimab.

• US pauses shipments of Eli Lilly’s COVID-19 antibody treatment due to variant concerns

  The US Department of Health and Human Services (HHS) decided to halt shipments of the antibody cocktail – comprised of bamlanivimab and etesevimab – after laboratory analyses found the therapy was not effective ... In April, the US Food and Drug

• EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19

  The mAb was also evaluated in the outpatient setting in the BLAZE-4 trial, sponsored by Eli Lilly, to assess the safety and efficacy of Lilly’s neutralising antibody bamlanivimab alone ... An interim analysis demonstrated that bamlanivimab plus